SERPINA1 and alpha 1-antitrypsin deficiency: In AATD-related COPD, identifying patients with poor lung function and those at risk of accelerated lung function decline is particularly relevant, as these patients should be optimised, which may include intravenous augmentation of plasma alpha-1 antitrypsin levels, although this treatment is not licensed in all countries [10,11].